BioSpace News Archive

Business

Novartis Pharmaceuticals Canada Inc. announces digital innovation partnership in multiple sclerosis with Innodem Neurosciences

Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce today a multi-year partnership agreement with Innodem Neurosciences to conduct a breakthrough clinical trial to help people living with multiple sclerosis.

October 5, 2021
·
4 min read
Drug Development

Kaleido Biosciences Announces New Clinical and Preclinical Data Supporting Advancement of KB295 to a Phase 2 Clinical Study in Mild-to-Moderate Ulcerative Colitis

Kaleido Biosciences, Inc. today announced topline data from the non-IND/CTA clinical study evaluating KB295, a novel Microbiome Metabolic Therapy (MMT™), in mild-to-moderate ulcerative colitis (UC).

October 5, 2021
·
10 min read
Business

Innodem Neurosciences Signs a Strategic Partnership with Novartis Pharmaceuticals Canada Inc.

Innodem Neurosciences announced today that it has signed a multi-year partnership agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to conduct a breakthrough clinical trial to help people living with multiple sclerosis (MS).

October 5, 2021
·
3 min read
Valeo Pharma Completes Negotiations with Pan-Canadian Pharmaceutical Alliance for Enerzair® Breezhaler® and Atectura® Breezhaler®

Valeo Pharma Inc., a Canadian pharmaceutical company, announced that it has completed its negotiations and entered into a letter of intent with the pan-Canadian Pharmaceutical Alliance regarding Enerzair Breezhaler and Atectura Breezhaler, its two innovative asthma therapies.

October 5, 2021
·
4 min read
Can-Fite to Present at H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021

Can-Fite to Present at H.C. Wainwright 5 th Annual NASH Investor Conference on October 12, 2021

October 5, 2021
·
5 min read
Business

Gemini Therapeutics Announces Corporate Restructuring to Prioritize Late-Stage Clinical Development of GEM103 for Geographic Atrophy

Gemini Therapeutics, Inc. today announced a corporate restructuring, including several executive officer transitions, to prioritize assets and focus on initiating and executing GEM103’s resource-intensive pivotal trial in geographic atrophy (GA).

October 5, 2021
·
7 min read
Genetown

Enanta Pharmaceuticals to Present at the H.C. Wainwright 2nd Annual Hepatitis B Virus Virtual Conference

Enanta Pharmaceuticals to Present at the H.C. Wainwright 2nd Annual Hepatitis B Virus Virtual Conference

October 5, 2021
·
1 min read
BioCapital

AZD7442 Request for Emergency Use Authorization for COVID-19 Prophylaxis Filed in US

Filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic COVID-19 with long-acting antibody combination (non-vaccine)

October 5, 2021
·
6 min read
Business

Taysha Announces Exclusive Option from UTSW to License Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program for CLN7 Disease

CLN7 program currently in Phase 1 clinical proof-of-concept trial with preliminary data anticipated by year-end 2021

October 5, 2021
·
9 min read
Pharm Country

Nephros to Present at the LD Micro Main Event

Nephros, Inc. today announced it has been selected to present at the 14th Annual LD Micro Main Event on Tuesday, October 12, 2021 at 12:30 pm ET at the Luxe Sunset Bel-Air in Los Angeles.

October 5, 2021
·
1 min read